<PAGE>

EXHIBIT 99.1


[LOGO] ADVANCED BIOTHERAPY, INC.
                                  ---------------------------------------------
                                  Administration
                                  6355 Topanga Canyon Boulevard, Suite 510
                                  Woodland Hills, California  91367

                                  Laboratories
                                  9110 Red Branch Rd.
                                  Columbia, MD 21045

                                  Telephone 818-883-6716
                                  Fax 818-883-3353
                                  www.advancedbiotherapy.com



                             "FOR IMMEDIATE RELEASE"

 Dr. Joseph A. Bellanti Rejoins Board of Directors of Advanced Biotherapy, Inc.

LOS ANGELES--(BUSINESS WIRE)--October 23, 2003

"Dr.  Bellanti's  experience as  immunologist  and virologist  pivotal to future
therapeutic strategies of Company"

Advanced  Biotherapy,  Inc  (OTCBB:ADVB  - News)  - a  developer  of  pioneering
antibody therapies for treating  widespread  autoimmune diseases - reported that
Dr. Joseph A. Bellanti,  Professor of Pediatrics and Microbiology-Immunology and
Director of the International Center for Interdisciplinary Studies of Immunology
at Georgetown University School of Medicine, has rejoined the Company's Board of
Directors.

Commenting on Dr. Bellanti's appointment, Edmond Buccellato, the Company's Chief
Executive  Officer and Chairman of the Board stated "We are extremely pleased to
have Dr.  Bellanti  rejoin our Board at this critical  point in time. As head of
our Scientific Advisory Committee,  Dr. Bellanti will not only act as scientific
liaison to the Board but will also  function as a key  scientific  spokesman for
the Company. In addition to the recognition he has received as a gifted educator
of medical  students,  residents,  fellows and  practicing  physicians,  he also
brings to the Company the vast clinical  experience he has attained  through his
continuing  direct  patient  care of  children  and adult  patients  with a wide
spectrum of allergic and  immunologic  disorders.  Dr. Bellanti is the author of
over 450 scientific  publications  and several book chapters and books including
his internationally recognized textbook, Immunology, now in its fourth edition.
 He is the  recipient  of numerous  awards  including  the  prestigious  E. Mead
Johnson Award for Excellence in Pediatric  Research from the American Academy of
Pediatrics and the Humanitarian  Award and the Fellow  Distinguished  Award from
the American College of Allergy,  Asthma & Immunology.  He is  past-president of
the  American  Board of  Allergy  and  Immunology,  the  Society  for  Pediatric
Research,  Interasma, the American College of Allergy, Asthma & Immunology,  and
the Association of Medical Laboratory  Immunologists.  He was editor in chief of
"Pediatric  Research"  from 1974 to 1984 and editor of "Annals of Allergy"  from
1982 to 1989.


<PAGE>

He received his MD degree from the University of Buffalo,  where his interest in
immunology was first  stimulated by his teacher and mentor,  Dr Ernest Witebsky,
the acknowledged  "Father of  Autoimmunity".  After completing  residency at the
Children's  Hospital Buffalo in 1961, he received  training in immunology at the
University of Florida  School of Medicine,  Gainesville in 1961-62 and continued
his studies as a research  virologist at Walter Reed Army Institute of Research,
Washington,  DC from  1962-64.  In 1963,  he joined the  faculty  of  Georgetown
University  School  of  Medicine  as  Assistant   Professor  of  Pediatrics  and
Microbiology,  where he rose to his current  position of Professor of Pediatrics
and  Microbiology-Immunology.  In 1975 he established and became Director of the
International Center for  Interdisciplinary  Studies of Immunology at Georgetown
University  School of  Medicine."

"Dr  Bellanti's  extensive and wide range of experience as an  immunologist  and
virologist are pivotal to the future therapeutic strategies being planned by the
Company", Mr. Buccellato concluded.


Commenting on his appointment,  Dr Bellanti  stated,  "I consider it an honor to
join the Board of Directors of Advanced  Biotherapy,  Inc,  particularly at this
critical juncture of growth and expansion of the Company. The Company's focus on
anti-cytokine  therapy  not only is a tribute to the  pioneering  and  visionary
contributions of Dr. Simon Skurkovich but also the cornerstone to the management
and control of a wide range of autoimmune disorders which only up until recently
were diagnostic and therapeutic orphans".

Autoimmune  diseases,  in  general,  are the result of an  inappropriate  immune
response in which the body's  immune  system  attacks its own healthy  cells and
organs.  In  these  disorders,   certain   chemicals,   called  cytokines,   are
hyperproduced  and  bring  about  the  autoimmune  condition.  One of  Company's
patented therapies is designed to remove or neutralize these excessive cytokines
known as interferon-gamma and tumor necrosis  factor-alpha,  which is induced by
interferon-gamma.  Removal of these agents is  accomplished  by the injection of
antibody  directed  to  these  proteins  following  which  dramatic   beneficial
therapeutic  effects are seen which could possibly form the basis of a universal
treatment for certain  types of autoimmune  diseases.  Advanced  Biotherapy  has
already achieved encouraging results in clinical trials in rheumatoid arthritis,
multiple  sclerosis and in the halting of corneal transplant  rejection,  Type 1
diabetes and a wide variety of autoimmune  skin disorders  (psoriasis  vulgaris,
alopecia areata, vitiligo, pemphigus vulgaris and epidermolysis bullosa).

About Advanced Biotherapy
Advanced  Biotherapy,  Inc.,  located  in  Los  Angeles,  with  laboratories  in
Columbia,  Maryland, is pioneering the development of new antibody therapies for
treating  severe  and  widespread   autoimmune  diseases.   Its  investigational
therapies  attack  autoimmune  diseases at their source,  neutralizing  biologic
imbalances  that impair immune  system  function.  Core  technology is protected
under U.S.  patents and  patents  pending  for the  exclusive  use of a class of
antibodies to the protein  known as  interferon-gamma,  and  antibodies to other
proteins, for treating a range of autoimmune diseases.

Statements made in this news release,  other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated  results or
other expectations  expressed in our forward-looking  statements.  The risks and
uncertainties  which may affect the  development,  operations and results of our
business  include,  but are not limited to the following:  risks associated with
clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory  approval process,  the risks of competitive
products,  the risks of our current capital  resources,  the uncertainties as to
the availability of future capital and our future capital requirements,  and the
risks associated with the extent and breadth of the Company's patent  portfolio.
The foregoing  discussion of the pending clinical  investigations and the effect
of the patents issued and pending  involves risks and  uncertainties,  including
but not limited to the risks that third parties may be successful in challenging
such  patents;  or that  granted  claims  may be  held  invalid  or  interpreted
differently by a court of law; or that new  technologies  will be developed that
are  superior in treating  the diseases  targeted by Advanced  Biotherapy,  Inc.
Readers are cautioned not to place reliance on these forward-looking statements,
which  speak only as of the date the  statements  were made.  See the  Company's
public  filings  with  the  Securities  and  Exchange   Commission  for  further
information  about risks and  uncertainties  that may affect the Company and the
results or expectations expressed in our forward-looking  statements,  including
the section  captioned  "Factors  That May Affect The Company"  contained in the
Company's  Annual  Report on Form 10-KSB for the fiscal year ended  December 31,
2002.


-----------------------
Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com

